CN109071429A - 丙啶磺酰胺类化合物及其使用方法 - Google Patents

丙啶磺酰胺类化合物及其使用方法 Download PDF

Info

Publication number
CN109071429A
CN109071429A CN201780018417.2A CN201780018417A CN109071429A CN 109071429 A CN109071429 A CN 109071429A CN 201780018417 A CN201780018417 A CN 201780018417A CN 109071429 A CN109071429 A CN 109071429A
Authority
CN
China
Prior art keywords
amino
chlorphenyl
oxoethyl
fluorophenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780018417.2A
Other languages
English (en)
Other versions
CN109071429B (zh
Inventor
祝力
杨艳青
戴丽光
段小伟
杨钊
张慧
胡远东
彭勇
韩永信
赵锐
田心
王善春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings (beijing) Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN109071429A publication Critical patent/CN109071429A/zh
Application granted granted Critical
Publication of CN109071429B publication Critical patent/CN109071429B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/22—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C07D203/24—Sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

具有异柠檬酸脱氢酶1（IDH1）抑制活性的丙啶磺酰胺类化合物，其药学上可接受的盐、溶剂化物或水合物、药物组合物，以及上述化合物或其药学上可接受的盐、溶剂化物或水合物和其药物组合物在治疗IDH1突变诱发的癌症中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201780018417.2A 2016-03-22 2017-03-22 丙啶磺酰胺类化合物及其使用方法 Active CN109071429B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016101661138 2016-03-22
CN201610166113 2016-03-22
PCT/CN2017/077611 WO2017162156A1 (zh) 2016-03-22 2017-03-22 丙啶磺酰胺类化合物及其使用方法

Publications (2)

Publication Number Publication Date
CN109071429A true CN109071429A (zh) 2018-12-21
CN109071429B CN109071429B (zh) 2021-04-02

Family

ID=59899237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780018417.2A Active CN109071429B (zh) 2016-03-22 2017-03-22 丙啶磺酰胺类化合物及其使用方法

Country Status (5)

Country Link
US (1) US11203586B2 (zh)
EP (1) EP3444237B1 (zh)
CN (1) CN109071429B (zh)
TW (1) TW201736341A (zh)
WO (1) WO2017162156A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113816887A (zh) * 2021-08-31 2021-12-21 华中科技大学 一种氮杂环丙烷类化合物及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115806532A (zh) * 2022-08-31 2023-03-17 大连百傲化学股份有限公司 一种mit中杂质的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012009678A1 (en) * 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
WO2013107405A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2012009678A1 (en) * 2010-07-16 2012-01-19 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their method of use
WO2013107405A1 (en) * 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015010297A1 (en) * 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113816887A (zh) * 2021-08-31 2021-12-21 华中科技大学 一种氮杂环丙烷类化合物及其制备方法

Also Published As

Publication number Publication date
EP3444237A4 (en) 2019-09-04
US20210155610A1 (en) 2021-05-27
EP3444237B1 (en) 2020-10-28
EP3444237A1 (en) 2019-02-20
US11203586B2 (en) 2021-12-21
CN109071429B (zh) 2021-04-02
TW201736341A (zh) 2017-10-16
WO2017162156A1 (zh) 2017-09-28

Similar Documents

Publication Publication Date Title
CN108516958B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
JP6419990B2 (ja) ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体
JP4324221B2 (ja) Ｐｐａｒアゴニスト活性を有する誘導体
AU2020349451B2 (en) BRD9 bifunctional degraders and their methods of use
CN113286794A (zh) Kras突变蛋白抑制剂
EP1615878A2 (en) Compounds, compositions and methods
WO2008038768A1 (fr) Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
WO2005115975A1 (ja) アリールアルキルアミン化合物及びその製法
WO2021043322A1 (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
CN107709298A (zh) 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
JP2011525924A (ja) プロリルヒドロキシラーゼ阻害剤
JP2019519606A (ja) チオフェン化合物、その合成方法及び医療における応用
TW200804318A (en) Non-anilinic derivatives of isothiazol-3(2H)-one 1, 1-dioxides as liver X receptor modulators
JPWO2018021447A1 (ja) ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
CN114685460A (zh) Kras g12c抑制剂及其在医药上的应用
TW202227397A (zh) 雙環的－雜環衍生物及相關用途
KR20220113773A (ko) 사이클린 의존성 키나아제 9 억제제로서의 화합물 및 그의 용도
CN109071429A (zh) 丙啶磺酰胺类化合物及其使用方法
JP2012121889A (ja) Ｈｄｌ上昇剤
CN114790164B (zh) 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
CN114163408B (zh) 苯并含氧杂环类化合物及其医药应用
WO2024086814A2 (en) Cyclin inhibitors
CN117551078A (zh) 芳香单环类衍生物及其制备方法和用途
TW202333663A (zh) Rxfp1促效劑
JP2020186182A (ja) 標的蛋白質分解誘導化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190531

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant